NSE: NH | BSE: 539551

Expensive Performer

Download real time

1768.30 -29.70 (-1.65%)

25.39% Fall from 52W High

154.2K NSE+BSE Volume

NSE 24 Apr, 2026 3:31 PM (IST)

36,137.1

Market Cap

High in industry

Beta 1Year

Very Low volatility

Narayana Hrudayalaya Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NH, BSE:539551 Narayana Hrudayalaya Ltd.

Search Inside the pdf :

Narayana Hrudayalaya Ltd.

24 Mar 2026, 12:00AM

1768.30

-1.65%

NARAYANA HRUDAYALAYA LIMITED

Hold: Narayana Hrudayalaya Ltd.

Recommendation Target

Geojit BNP Paribas

Narayana Health reported a healthy topline performance in 9MFY26, though EBITDA margins remained under pressure due to the ongoing integration of its U.K. operations. Looking ahead, the planned addition of ~1,500 beds over the next three to five years...

Narayana Hrudayalaya Ltd. is trading below its 100 day SMA of 1807.2

Narayana Hrudayalaya Ltd.

06 Mar 2026

1768.30

-1.65%

BP Equities Narayana Hrudaylaya Ltd. Shining Star Series BUY Target 2,110

Buy: Narayana Hrudayalaya Ltd.

BP Wealth

Number of FII/FPI investors decreased from 354 to 321 in Mar 2026 qtr

Narayana Hrudayalaya Ltd.

18 Feb 2026

1768.30

-1.65%

Narayana Hrudayalaya (NARH IN) Q3FY26 Result Update Another strong quarter across India & Cayman BUY

Buy: Narayana Hrudayalaya Ltd.

Target

Prabhudas Lilladhar

Narayana Hrudayalaya (NARH) reported strong EBITDA of Rs4.4bn (up 44% YoY) adjusted for one time cost, 7% above our estimates driven by robust performance across India and Cayman operations along with consolidation of UK subsidiary. The Cayman business reported profitability of Rs1.88bn (up 42% YoY) adj for CHIL losses. India business reported healthy EBITDA adjusted for NHIC losses, up ~24% YoY. The management reiterated its aggressive capex...

Narayana Hrudayalaya Ltd. is trading below its 100 day SMA of 1807.2

Narayana Hrudayalaya Ltd.

19 Dec 2025

1768.30

-1.65%

Health for all. All for health.

Buy: Narayana Hrudayalaya Ltd.

Target

FundsIndia

Edge: High-acuity care + efficiency-led growth + ecosystem integration

Narayana Hrudayalaya Ltd. is trading above its 50 day SMA of 1753.7

Narayana Hrudayalaya Ltd.

04 Nov 2025

1768.30

-1.65%

Narayana Hrudayalaya (NARH IN) Event Update Expands global...

Buy: Narayana Hrudayalaya Ltd.

Prabhudas Lilladhar

Narayana Hrudayalaya Ltd. is trading below its 100 day SMA of 1807.2

Narayana Hrudayalaya Ltd.

20 Aug 2025

1768.30

-1.65%

NARAYANA HRUDAYALAYA LIMITED

Sell: Narayana Hrudayalaya Ltd.

Target

Geojit BNP Paribas

In Q1FY26, Narayana Hrudayalaya delivered stable topline performance, though EBITDA margins were impacted by losses in the Integrated Care segment. The segment remains dilutive, with elevated costs weighing on consolidated profitability. With a pipeline of...

Number of FII/FPI investors decreased from 354 to 321 in Mar 2026 qtr

Narayana Hrudayalaya Ltd.

11 Aug 2025

1768.30

-1.65%

Losses from CIHL drag on overall performance; maintaining a Buy

Buy: Narayana Hrudayalaya Ltd.

Target

Anand Rathi

Below our estimate (mainly losses at Cayman Integrated Healthcare), Narayana Hrudayalaya’s Q1 EBITDA was Rs3.4bn, up 11% y/y, 7% q/q.

Narayana Hrudayalaya Ltd. is trading above its 50 day SMA of 1753.7

Narayana Hrudayalaya Ltd.

05 Aug 2025

1768.30

-1.65%

Narayana Hrudayalaya (NARH IN) Q1FY26 Result Update EBITDA...

Buy: Narayana Hrudayalaya Ltd.

Target

Prabhudas Lilladhar

Narayana Hrudayalaya (NARH) reported EBITDA of Rs3.4bn (up 11% YoY) in Q1FY26, 4% below our estimates due to losses at Cayman Integrated Healthcare business. The Cayman business reported profitability of Rs1.44bn (up 17% YoY), adjusted for CIHL losses, up 25% YoY. India business reported healthy EBITDA adjusted for NHIC losses, up 13% YoY. The management reiterated its aggressive capex plan and commitment towards growing throughput over the next 3-4 years through debottlenecking, refurbishment...

Number of FII/FPI investors decreased from 354 to 321 in Mar 2026 qtr

Narayana Hrudayalaya Ltd.

30 Jun 2025

1768.30

-1.65%

NARAYANA HRUDAYALAYA LIMITED

Sell: Narayana Hrudayalaya Ltd.

Recommendation Target

Geojit BNP Paribas

Narayana continues to deliver stable performance, driven by improved throughput rather than bed expansion. While the Indian business remained steady in FY25, the Cayman segment outperformed with 50% YoY sales growth and margin gains in Q4FY25. In our...

Narayana Hrudayalaya Ltd. is trading above its 50 day SMA of 1753.7

Is Narayana Hrudayalaya Ltd. worth buying?

228 Votes:

Buy 80.7%

Sell 14.47%

Hold 4.82%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf